The Patent Finder

Maintenance fees coming due

Forma Therapeutics, Inc.

12 maintenance fees come due in the 12 months from Nov 16, 2026, the next on Feb 15, 2027. Unpaid by Aug 16, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5 and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the six month grace period that follows.
PatentTitleHolderStatusFee dueLapses if unpaidExpiresConfidence
US 11,723,905Solid Forms of ((S)-5-((1-(6-Chloro-2-OXO-1,2-Dihydroquinolin-3-YL)ETHYL)AMINO)-1-Methyl-6-OXO-1,6-Dihydropyridine-2-Carbonitrile
In force
Fee due Feb 15, 2027
Lapses if unpaid Aug 16, 2027
 · High confidence
Forma Therapeutics, Inc.In forceFeb 15, 2027Aug 16, 2027High confidence
US 11,738,018Inhibiting Mutant Isocitrate Dehydrogenase 1 (mIDH-1)
In force
Fee due Feb 28, 2027
Lapses if unpaid Aug 30, 2027
 · High confidence
Forma Therapeutics, Inc.In forceFeb 28, 2027Aug 30, 2027High confidence
US 10,399,980Purinones as Ubiquitin-Specific Protease 1 Inhibitors
In force
Fee due Mar 3, 2027
Lapses if unpaid Sep 3, 2027
 · High confidence
Forma Therapeutics, Inc.In forceMar 3, 2027Sep 3, 2027High confidence
US 10,414,752PYRIDIN-2(1H)-ONE Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors
In force
Fee due Mar 17, 2027
Lapses if unpaid Sep 17, 2027
 · Low confidence
Forma Therapeutics, Inc.In forceMar 17, 2027Sep 17, 2027Low confidence
US 11,787,803Tetrahydro-Imidazo Quinoline Compositions as CBP/P300 Inhibitors
In force
Fee due Apr 17, 2027
Lapses if unpaid Oct 18, 2027
 · High confidence
Forma Therapeutics, Inc.In forceApr 17, 2027Oct 18, 2027High confidence
US 11,795,168Inhibiting Cyclic Amp-Responsive Element-Binding Protein (CREB) Binding Protein (CBP)
In force
Fee due Apr 24, 2027
Lapses if unpaid Oct 25, 2027
 · High confidence
Forma Therapeutics, Inc.In forceApr 24, 2027Oct 25, 2027High confidence
US 11,801,243Bromodomain Inhibitors for Androgen Receptor-Driven Cancers
In force
Fee due Apr 30, 2027
Lapses if unpaid Nov 1, 2027
 · High confidence
Forma Therapeutics, Inc.In forceApr 30, 2027Nov 1, 2027High confidence
US 11,814,386Fused Pyrrolines Which Act as Ubiquitin-Specific Protease 30 (USP30) Inhibitors
In force
Fee due May 14, 2027
Lapses if unpaid Nov 15, 2027
 · High confidence
Forma Therapeutics, Inc.In forceMay 14, 2027Nov 15, 2027High confidence
US 10,532,047Solid Forms of ((S)-5-((1-(6-Chloro-2-OXO-1,2-Dihydroquinolin-3-YL)ETHYL)AMINO)-1-Methyl-6-OXO-1,6-Dihydropyridine-2-Carbonitrile
In force
Fee due Jul 14, 2027
Lapses if unpaid Jan 14, 2028
 · High confidence
Forma Therapeutics, Inc.In forceJul 14, 2027Jan 14, 2028High confidence
US 10,550,098PYRIDIN-2(1H)-ONE Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors
In force
Fee due Aug 4, 2027
Lapses if unpaid Feb 4, 2028
 · Low confidence
Forma Therapeutics, Inc.In forceAug 4, 2027Feb 4, 2028Low confidence
2 more maintenance fees coming due in the 12 months from Nov 16, 2026 · Pro
10 of 12 patents shown. Soonest fee due date first, then patent number.
Pro members see every patent with a maintenance fee coming due: number, title, status, the due date, and the date it lapses if the fee goes unpaid through the grace period.
Upgrade to Pro
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited